Mislabeling of drug for Kaposi's sarcoma rectified.
D017326:Clinical Trials, Phase III as Topic; D003630:Daunorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004348:Drug Labeling; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D008081:Liposomes; D003630:Daunorubicin